Gene Page:CYLD
概括?
基因 | 1540 |
Symbol | CYLD |
Synonyms | BRSS|CDMT|CYLD1|CYLDI|EAC|MFT|MFT1|SBS|TEM|USPL2 |
Description | CYLD lysine 63 deubiquitinase |
Reference | MIM:605018|HGNC:HGNC:2584|Ensembl:ENSG00000083799|HPRD:05427|Vega:OTTHUMG00000173404 |
Gene type | protein-coding |
Map location | 16q12.1 |
Pascal p-value | 0.01 |
Sherlock p-value | 0.811 |
eGene | Myers' cis & trans |
Support | G2Cdb.human_BAYES-COLLINS-HUMAN-PSD-FULL G2Cdb.human_BAYES-COLLINS-MOUSE-PSD-CONSENSUS G2Cdb.humanPSD G2Cdb.humanPSP |
数据源中的基因
Gene set name | Method of gene set | Description | Info |
---|---|---|---|
CV:PGCnp | Genome-wide Association Study | GWAS | |
GSMA_IIE | Genome scan meta-analysis (European-ancestry samples) | Psr: 0.01775 |
Section I. Genetics and epigenetics annotation
eQTL annotation
SNP ID | Chromosome | Position | eGene | Gene Entrez ID | pvalue | qvalue | TSS distance | eQTL type |
---|---|---|---|---|---|---|---|---|
RS17432174 | chr6 | 37290840 | CYLD | 1540 | 0.19 | trans | ||
RS10898193 | chr11 | 71197082 | CYLD | 1540 | 0.06 | trans | ||
rs11233977 | chr11 | 71221604 | CYLD | 1540 | 0.07 | trans | ||
rs4366501 | chr11 | 133380324 | CYLD | 1540 | 0.14 | trans | ||
rs6574512 | chr14 | 26077513 | CYLD | 1540 | 0.03 | trans |
Section II. Transcriptome annotation
General gene expression (GTEx)
![Not available](http://www.tjghsg.com/bioinfo/SZGR/GeneImg/CYLD_DE_GTEx.png)
Gene expression of temporal and spatial changes (BrainSpan)
Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
某羊乳酪l (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes the lower 25% and upper 25% of the expression distribution.
No co-expressed genes in brain regions
Section III. Gene Ontology annotation
Molecular function | 去的术语 | Evidence | Neuro keywords | PubMed ID |
---|---|---|---|---|
GO:0003735 | 核糖体的结构成分 | IEA | - | |
GO:0004221 | 泛素thiolesterase活动 | NAS | - | |
GO:0008234 | cysteine-type peptidase activity | IEA | - | |
GO:0008233 | peptidase activity | IEA | - | |
生物过程 | 去的术语 | Evidence | Neuro keywords | PubMed ID |
GO:0006511 | ubiquitin-dependent protein catabolic process | NAS | - | |
GO:0006412 | translation | IEA | - | |
GO:0045786 | negative regulation of cell cycle | IEA | - | |
Cellular component | 去的术语 | Evidence | Neuro keywords | PubMed ID |
GO:0005840 | 核糖体 | IEA | - | |
GO:0005856 | cytoskeleton | NAS | 10835629 | |
GO:0005622 | intracellular | IEA | - | |
GO:0005737 | cytoplasm | IEA | - |
Section V. Pathway annotation
Pathway name | Pathway size | # SZGR 2.0 genes in pathway | Info |
---|---|---|---|
KEGG RIG I LIKE RECEPTOR SIGNALING PATHWAY | 71 | 51 | 该途径中的所有SZGR 2.0基因 |
PID NFKAPPAB CANONICAL PATHWAY | 23 | 20 | 该途径中的所有SZGR 2.0基因 |
PID TNF途径 | 46 | 33 | 该途径中的所有SZGR 2.0基因 |
REACTOME NEGATIVE REGULATORS OF RIG I MDA5 SIGNALING | 31 | 19 | 该途径中的所有SZGR 2.0基因 |
REACTOME RIG I MDA5 MEDIATED INDUCTION OF IFN ALPHA BETA PATHWAYS | 73 | 57 | 该途径中的所有SZGR 2.0基因 |
REACTOME INNATE IMMUNE SYSTEM | 279 | 178 | 该途径中的所有SZGR 2.0基因 |
REACTOME IMMUNE SYSTEM | 933 | 616 | 该途径中的所有SZGR 2.0基因 |
REACTOME NOD1 2 SIGNALING PATHWAY | 30 | 22 | 该途径中的所有SZGR 2.0基因 |
REACTOME NUCLEOTIDE BINDING DOMAIN LEUCINE RICH REPEAT CONTAINING RECEPTOR NLR SIGNALING PATHWAYS | 46 | 33 | 该途径中的所有SZGR 2.0基因 |
ZHONG RESPONSE TO AZACITIDINE AND TSA UP | 183 | 119 | 该途径中的所有SZGR 2.0基因 |
DEURIG T CELL PROLYMPHOCYTIC LEUKEMIA DN | 320 | 184 | 该途径中的所有SZGR 2.0基因 |
CHARAFE BREAST CANCER LUMINAL VS BASAL DN | 455 | 304 | 该途径中的所有SZGR 2.0基因 |
OSWALD HEMATOPOIETIC STEM CELL IN COLLAGEN GEL DN | 275 | 168 | 该途径中的所有SZGR 2.0基因 |
RODRIGUES THYROID CARCINOMA POORLY DIFFERENTIATED DN | 805 | 505 | 该途径中的所有SZGR 2.0基因 |
RODRIGUES THYROID CARCINOMA ANAPLASTIC DN | 537 | 339 | 该途径中的所有SZGR 2.0基因 |
Scheidereit IKK目标 | 18 | 15 | 该途径中的所有SZGR 2.0基因 |
DUTTA APOPTOSIS VIA NFKB | 33 | 25 | 该途径中的所有SZGR 2.0基因 |
Scheidereit IKK相互作用蛋白 | 58 | 45 | 该途径中的所有SZGR 2.0基因 |
TOMLINS PROSTATE CANCER DN | 40 | 33 | 该途径中的所有SZGR 2.0基因 |
NUYTTEN EZH2 TARGETS UP | 1037 | 673 | 该途径中的所有SZGR 2.0基因 |
FERREIRA EWINGS SARCOMA UNSTABLE VS STABLE DN | 98 | 59 | 该途径中的所有SZGR 2.0基因 |
BENPORATH NANOG TARGETS | 988 | 594 | 该途径中的所有SZGR 2.0基因 |
STEGMEIER PRE-MITOTIC CELL CYCLE REGULATORS | 11 | 8 | 该途径中的所有SZGR 2.0基因 |
BASSO B LYMPHOCYTE NETWORK | 143 | 96 | 该途径中的所有SZGR 2.0基因 |
XU GH1 AUTOCRINE TARGETS UP | 268 | 157 | 该途径中的所有SZGR 2.0基因 |
WANG SMARCE1 TARGETS UP | 280 | 183 | 该途径中的所有SZGR 2.0基因 |
KRIGE RESPONSE TO TOSEDOSTAT 6HR UP | 953 | 554 | 该途径中的所有SZGR 2.0基因 |
KRIGE RESPONSE TO TOSEDOSTAT 24HR UP | 783 | 442 | 该途径中的所有SZGR 2.0基因 |
MARSON BOUND BY FOXP3 STIMULATED | 1022 | 619 | 该途径中的所有SZGR 2.0基因 |
MASSARWEH TAMOXIFEN RESISTANCE UP | 578 | 341 | 该途径中的所有SZGR 2.0基因 |
DE YY1 TARGETS DN | 92 | 64 | 该途径中的所有SZGR 2.0基因 |
Smid乳腺癌正常 | 476 | 285 | 该途径中的所有SZGR 2.0基因 |
BONOME OVARIAN CANCER SURVIVAL OPTIMAL DEBULKING | 246 | 152 | 该途径中的所有SZGR 2.0基因 |
BOQUEST STEM CELL CULTURED VS FRESH UP | 425 | 298 | 该途径中的所有SZGR 2.0基因 |
FIRESTEIN PROLIFERATION | 175 | 125 | 该途径中的所有SZGR 2.0基因 |
GRESHOCK CANCER COPY NUMBER UP | 323 | 240 | 该途径中的所有SZGR 2.0基因 |
LEE EARLY T LYMPHOCYTE DN | 57 | 36 | 该途径中的所有SZGR 2.0基因 |
POOLA INVASIVE BREAST CANCER UP | 288 | 168 | 该途径中的所有SZGR 2.0基因 |
Yagi AML与T 9 11易位 | 130 | 87 | 该途径中的所有SZGR 2.0基因 |
开罗肝母细胞瘤课程DN | 210 | 141 | 该途径中的所有SZGR 2.0基因 |
CAIRO LIVER DEVELOPMENT DN | 222 | 141 | 该途径中的所有SZGR 2.0基因 |
ZHAN MULTIPLE MYELOMA PR DN | 44 | 34 | 该途径中的所有SZGR 2.0基因 |
Sengupta EBNA1反相关 | 173 | 85 | 该途径中的所有SZGR 2.0基因 |
PILON KLF1 TARGETS UP | 504 | 321 | 该途径中的所有SZGR 2.0基因 |
PILON KLF1 TARGETS DN | 1972 | 1213 | 该途径中的所有SZGR 2.0基因 |
GOBERT OLIGODENDROCYTE DIFFERENTIATION DN | 1080 | 713 | 该途径中的所有SZGR 2.0基因 |
IKEDA MIR133 TARGETS UP | 43 | 27 | 该途径中的所有SZGR 2.0基因 |
WAKABAYASHI ADIPOGENESIS PPARG BOUND 8D | 658 | 397 | 该途径中的所有SZGR 2.0基因 |
PHONG TNF RESPONSE VIA P38 PARTIAL | 160 | 106 | 该途径中的所有SZGR 2.0基因 |
PHONG TNF RESPONSE NOT VIA P38 | 337 | 236 | 该途径中的所有SZGR 2.0基因 |
BOSCO ALLERGEN INDUCED TH2 ASSOCIATED MODULE | 151 | 86 | 该途径中的所有SZGR 2.0基因 |
Section VI. microRNA annotation
miRNA family | Target position | miRNA ID | miRNA seq | ||
---|---|---|---|---|---|
UTR start | UTR end | Match method | |||
miR-101 | 5052 | 5058 | m8 | HSA-MIR-101 | UACAGUACUGUGAUAACUGAAG |
miR-124.1 | 5326 | 5332 | 1A | hsa-miR-124a | UUAAGGCACGCGGUGAAUGCCA |
miR-130/301 | 190 | 196 | m8 | hsa-miR-130abrain | CAGUGCAAUGUUAAAAGGGCAU |
hsa-miR-301 | CAGUGCAAUAGUAUUGUCAAAGC | ||||
hsa-miR-130bbrain | Cagugcaaugaagggauggau | ||||
hsa-miR-454-3p | UAGUGCAAUAUUGCUUAUAGGGUUU | ||||
miR-182 | 3054 | 3061 | 1A,m8 | hsa-miR-182 | UUUGGCAAUGGUAGAACUCACA |
miR-19 | 189 | 195 | m8 | hsa-miR-19a | UGUGCAAAUCUAUGCAAAACUGA |
hsa-miR-19b | ugugcaaauccaugcaaaacuga | ||||
miR-409-3p | 5097 | 5104 | 1A,m8 | hsa-miR-409-3p | CGAAUGUUGCUCGGUGAACCCCU |
- SZ: miRNAs which differentially expressed in brain cortex of schizophrenia patients comparing with control samples using microarray. Clickhereto see the list of SZ related miRNAs.
- Brain: miRNAs which are expressed in brain based on miRNA microarray expression studies. Clickhereto see the list of brain related miRNAs.